ZUM GEGENWAERTIGEN STAND DER PLASMOZYTOMTHERAPIE = ETAT ACTUEL DU TRAITEMENT DU PLASMOCYTOMEIHLE R; STOBBE H; HAASE J et al.1976; DTSCHE GESUNDH.-WES.; DTSCH.; DA. 1976; VOL. 31; NO 23; PP. 1085-1089; ABS. RUSSE ANGL.; BIBL. 59 REF.Article

Acute cytotoxicity and apoptotic effects after L-Pam exposure in different cocultures of the proximal and distal respiratory systemPOHL, Christine; HOFMANN, Helene; MOISCH, Michaela et al.Journal of biotechnology. 2010, Vol 148, Num 1, pp 31-37, issn 0168-1656, 7 p.Conference Paper

ANTICORPS VIS-A-VIS DE LA SARCOLYSINE ET DU FLUOROURACILEMIL'MAN M SH; CHIRKINA YU M; SHEK BA et al.1974; VAPR. ONKOL.; S.S.S.R.; DA. 1974; VOL. 20; NO 6; PP. 91-95; ABS. ANGL.; BIBL. 10REF.Article

IMMUNOTHERAPY OF CANCER WITH L-PHENYLALANINE MUSTARD AS A HAPTEN = IMMUNOTHERAPIE DU CANCER AU MOYEN DE MOUTARDE A LA L-PHENYLALANINE EN TANT QU'HAPTENEARAI K; WALLACE HW; BLAKEMORE WS et al.1973; CANCER RES.; U.S.A.; DA. 1973; VOL. 33; NO 8; PP. 1914-1920; BIBL. 29REF.Serial Issue

ACTION COMPAREE DES PREPARATIONS POLYMERES ET DE LA SARCOLYSINE SUR L'HEMATOPOIESE CHEZ LE RATSAMOJLOVICH LI; ZUBOVA OV.1973; NAUK. DOKL. VYSSH. SHK., BIOL. NAUKI; S.S.S.R.; DA. 1973; VOL. 16; NO 2; PP. 42-45; BIBL. 8REF.Serial Issue

CELLULES SOUCHES HEMATOPOIETIQUE DES GANGLIONS LYMPHATIQUES DE LA SOURIS EN CAS DE METAPLASIE MYELOIDE DU TISSU LYMPHOIDE, PROVOQUE PAR LA SARCOLYSINEBODYAGIN DA; SVET MOLDAVSKAYA IA.1973; FARMAKOL. I TOKOIKOL.; S.S.S.R.; DA. 1973; VOL. 36; NO 3; PP. 349-352; BIBL. 7REF.Serial Issue

INTERACTION ENTRE L'ADN ET LES COMPOSES ALKYLANTS DE CLASSES DIFFERENTESYAMSHANOV VA; KRAJZ BO; PETROV AS et al.1973; VOPR. ONKOL.; S.S.S.R.; DA. 1973; VOL. 19; NO 2; PP. 60-62; ABS. ANGL.; BIBL. 7REF.Serial Issue

TREATMENT OF PRIMARY RENAL AMYLOIDOSIS WITH MELPHALAN = TRAITEMENT DE L'AMYLOSE RENALE PRIMITIVE PAR LE MELPHALANJONES NF; HILTON PJ; TIGHE JR et al.1972; LANCET; G.B.; DA. 1972; NO 7778; PP. 616-619; BIBL. 29REF.Serial Issue

RESULTATS DE L'UTILISATION DU MELPHALAN INTRAVEINEUX AU COURS DU MYELOME MULTIPLEBALMES A; DAUVERCHAIN J; OTHONIEL J et al.1973; LYON MEDITERR. MED.; FR.; DA. 1973; VOL. 9; NO 6; PP. 455-480 (16P.)Serial Issue

HYDROLYSE DE LA SARCOLYSINE DANS DES SOLUTIONS AQUEUSES DE QUELQUES COMPOSES MACROMOLECULAIRES ET DANS DES SOLUTIONS D'ACIDE CHLORHYDRIQUESAFONOV VP; LITVINOVA TP; LOPATIN PV et al.1973; FARMACIJA; S.S.S.R.; DA. 1973; VOL. 22; NO 3; PP. 20-24; ABS. ANGL.; BIBL. 13REF.Serial Issue

CORRELATION ENTRE LA STRUCTURE DE DERIVES DE LA SARCOLYSINE ET LEUR ACTIVITE ANTITUMORALE ET LEUR TOXICITELAUKAJTIS VA.1972; VOPR. ONKOL.; S.S.S.R.; DA. 1972; VOL. 18; NO 9; PP. 83-84Serial Issue

CONSIDERATIONS SUR LE TRAITEMENT DU MYELOME MULTIPLE PAR LE MELPHALAN INTRAVEINEUXBALMES A; DAUVERCHAIN J; VOYER MF et al.1973; LYON MEDITERR. MED.; FR.; DA. 1973; VOL. 9; NO 6; PP. 483-532 (30P.); BIBL. 2P.1/2Serial Issue

TRAITEMENT DE LA MALADIE MYELOMIQUE (PLASMOCYTOME GENERALISE)ANDREEVA NE; ANTIPOVA LG.1975; PROBL. GEMATOL. PERELIV. KROVI; S.S.S.R.; DA. 1975; VOL. 20; NO 3; PP. 51-57; BIBL. 1P.Serial Issue

COMBINATION CHEMOTHERAPY FOR MULTIPLE MYELOMAALEXANIAN R; BONNET J; GEHAN E et al.1972; CANCER; U.S.A.; DA. 1972; VOL. 30; NO 2; PP. 382-389; BIBL. 14REF.Serial Issue

PLASMA CELL MYELOMA: RESPONSE OF MELPHALAN-RESISTANT PATIENTS TO HIGH-DOSE INTERMITTENT CYCLOPHOSPHAMIDE = MYELOME A PLASMOCYTE: REACTION DES MALADES RESISTANTS AU MELPHALAN A UNE FORTE POSOLOGIE INTERMITTENTE DE CYCLOPHOSPHAMIDEBERGSAGEL DE; COWAN DH; HASSELBACK R et al.1972; CANAD. MED. ASS. J.; CANADA; DA. 1972; VOL. 107; NO 9; PP. 851-855; BIBL. 24REF.Serial Issue

ACUTE LEUKAEMIA AFTER FOUR YEARS OF MELPHALAN TREATMENT FOR MELANOMA.BURTON IE; ABBOTT CR; ROBERTS BE et al.1976; BRIT. MED. J.; G.B.; DA. 1976; NO 6000; PP. 20; BIBL. 3 REF.Article

THE STABILITY OF MELPHALAN IN THE PRESENCE OF CHLORIDE IONCHANG SY; EVANS TL; ALBERTS DS et al.1979; J. PHARM. PHARMACOL.; GBR; DA. 1979; VOL. 31; NO 12; PP. 853-854; BIBL. 7 REF.Article

The kinase inhibitor O⁶-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2HARRISON, Luke R. E; OTTLEY, Christopher J; PEARSON, D. Graham et al.Biochemical pharmacology. 2009, Vol 77, Num 10, pp 1586-1592, issn 0006-2952, 7 p.Article

Interpreting cell cycle effects of drugs : the case of melphalanLUPI, Monica; CAPPELLA, Paolo; MATERA, Giada et al.Cancer chemotherapy and pharmacology. 2006, Vol 57, Num 4, pp 443-457, issn 0344-5704, 15 p.Article

Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m²)PALUMBO, A; BRINGHEN, S; MUSTO, P et al.Leukemia. 2004, Vol 18, Num 1, pp 133-138, issn 0887-6924, 6 p.Article

Structure-activity relationship for alkylating dipeptide nitrogen mustard derivativesGULLBO, Joachim; TULLBERG, Marcus; VABENØ, Jon et al.Oncology research. 2003, Vol 14, Num 3, pp 113-132, issn 0965-0407, 20 p.Article

Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors: Clinical articlePETERSON, Eric C; MOHAMED SAMY ELHAMMADY; QUINTERO-WOLFE, Stacey et al.Journal of neurosurgery. 2011, Vol 114, Num 6, pp 1603-1608, issn 0022-3085, 6 p.Article

Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipientsNATH, Christa E; SHAW, Peter J; MONTGOMERY, Kay et al.British journal of clinical pharmacology. 2007, Vol 64, Num 2, pp 151-164, issn 0306-5251, 14 p.Article

Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complexGOMEZ-BOUGIE, Patricia; OLIVER, Lisa; LE GOUILL, Steven et al.Oncogene (Basingstoke). 2005, Vol 24, Num 54, pp 8076-8079, issn 0950-9232, 4 p.Article

Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignanciesMOUGENOT, Philippe; PINGUET, Frédéric; FABBRO, Michel et al.Cancer chemotherapy and pharmacology. 2004, Vol 53, Num 6, pp 503-512, issn 0344-5704, 10 p.Article